BioSpace News Archive

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 23rd Annual Needham Virtual Healthcare Conference.

G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023.

Grants to be awarded to early-career scientists for pioneering research in immunology, vaccine discovery, and immunotherapy research

Scientific Industries, Inc. announced it filed a Form 10K on March 29, 2024, for its full year financial results ended December 31, 2023, and issued a press release reporting its full year 2023 before the market open on April 1, 2024.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that it will host a conference call and live webcast to provide a business update with certain financials for the year ending December 31, 2023 at 8:30 a.m. ET on Tuesday, April 2, 2024.

Ocugen, Inc. announced that the Data Safety and Monitoring Board for the OCU410ST clinical trial recently convened and approved to proceed dosing with the medium dose of OCU410ST in the dose-escalation phase of the study.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas.

The American Academy of Orthopaedic Surgeons announced a call for proposals for the AAOS IDEA Grant Program®, a multi-year initiative to inspire diversity, equity and access across the field of orthopaedics.

The global microbiology testing market size was valued at USD 5.33 billion in 2023 and it is expected to surpass around USD 12.72 billion by 2033 with a CAGR of 9.12% from 2024 to 2033 due to the increasing demand for genetic testing services.